Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Kavar Capital Partners Group LLC

Kavar Capital Partners Group LLC lessened its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 12.7% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 9,497 shares of the medical research company’s stock after selling 1,380 shares during the period. Kavar Capital Partners Group LLC’s holdings in Edwards Lifesciences were worth $703,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of EW. FSA Wealth Management LLC acquired a new position in Edwards Lifesciences in the 3rd quarter worth approximately $30,000. Prospera Private Wealth LLC purchased a new stake in Edwards Lifesciences in the 3rd quarter worth about $32,000. Avior Wealth Management LLC lifted its stake in Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after acquiring an additional 308 shares in the last quarter. Peoples Bank KS acquired a new stake in Edwards Lifesciences during the 3rd quarter worth about $40,000. Finally, JFS Wealth Advisors LLC increased its holdings in shares of Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 166 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the sale, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. This represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 33,000 shares of company stock worth $2,195,180. Company insiders own 1.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $82.00 to $90.00 in a research report on Monday, December 16th. Evercore ISI lowered their price target on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a report on Tuesday, October 1st. JPMorgan Chase & Co. increased their price objective on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. The Goldman Sachs Group boosted their target price on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. Finally, Sanford C. Bernstein upgraded Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, Edwards Lifesciences presently has an average rating of “Hold” and a consensus price target of $78.48.

Edwards Lifesciences Stock Up 0.1 %

EW opened at $68.98 on Monday. The business has a 50 day moving average of $72.33 and a 200-day moving average of $70.36. The stock has a market capitalization of $40.68 billion, a price-to-earnings ratio of 9.95, a P/E/G ratio of 3.54 and a beta of 1.11. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.67. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business’s quarterly revenue was up 8.9% on a year-over-year basis. During the same period last year, the business posted $0.59 EPS. As a group, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.